RBC Capital Maintains Underperform on Amrize, Lowers Price Target to $32

Benzinga · 1d ago
RBC Capital analyst Anthony Codling maintains Amrize (NYSE:AMRZ) with a Underperform and lowers the price target from $48 to $32.